Last updated: July 27, 2026
What is phytonadione, and what key clinical-trial activity is underway?
Phytonadione (vitamin K1) is used to treat or prevent vitamin K deficiency and its consequences (notably bleeding due to hypoprothrombinemia). The product category includes multiple approved dosage forms and strengths across oral and injectable presentations, typically positioned in indications such as:
- Treatment of vitamin K deficiency with bleeding risk
- Antidote therapy in warfarin-associated coagulopathy in some labeling contexts (jurisdiction-dependent)
- Prevention of vitamin K deficiency in newborns (labeling varies by country and formulation)
- Supportive care in malabsorption-related deficiency states
Clinical-trials signal (what to track)
The drug’s clinical-trials footprint is dominated by:
- Formulation and bioequivalence studies for generics and authorized variants
- Observational studies and registry-type work
- Anticoagulant reversal and coagulopathy management studies where vitamin K is an intervention comparator
Featured trial types that tend to appear in the literature
- Oral vs. parenteral timing and co-administration studies (dose-response and time-to-INR correction)
- Safety and PK/PD studies in neonates, older adults, and malabsorption populations
- Hospital protocol and real-world effectiveness evaluations (bleeding outcomes, INR normalization)
Which phytonadione formulations are in clinical development or being studied for new evidence?
Across phytonadione development, the active work typically centers on drug product attributes rather than new pharmacology:
Injectable phytonadione
Common study themes:
- Solvent system, particle/sterility assurance, and administration parameters (IM/IV)
- Co-administration with anticoagulants or reversal protocols
- Time-to-coagulation correction endpoints (INR/prothrombin time)
Oral phytonadione
Common study themes:
- Bioavailability and dissolution-related performance
- Variant strengths and pediatric dosing feasibility
- Switching studies (parenteral to oral after stabilization)
Neonatal and pediatric contexts
Common study themes:
- Administration route and dosing schedules
- Safety in preterm populations
- Exposure comparisons among formulations
When does phytonadione lose exclusivity, and what does that mean for market competition?
Phytonadione is a mature, off-patent vitamin product in most major markets. In practice, “exclusivity” is less about novel active substance IP and more about:
- Remaining product-level protections for specific formulations (if any)
- Reference product exclusivity periods that may apply to particular brand/RLDs in certain jurisdictions (varies widely)
- Pediatric exclusivity or data exclusivity only when tied to specific new approvals (again formulation/brand-specific)
Business implication
Market entry and price competition typically track:
- Generic approvals by formulation and strength
- Hospital formulary conversion cycles
- Reimbursement tender cycles and bulk procurement norms
What patents protect phytonadione, and how strong is the IP estate?
A complete, product-by-product patent landscape is required to rank strength across jurisdictions, and IP coverage is highly dependent on the specific dosage form (injectable vs oral), strength, and the referenced brand/RLD.
Given the time-tested, widely available status of phytonadione, the practical IP posture usually indicates:
- Limited active-substance protection
- Potential pockets of formulation or process patenting for select branded presentations
- Low risk of long, broad exclusion akin to modern small-molecule NME/IP estates
What is the Orange Book status of phytonadione in the US?
The Orange Book listing status for phytonadione depends on the specific NDA/ANDA product and dosage form. In the US market, phytonadione is widely available through generics, and Orange Book “patent” coverage, where present, generally reflects product-specific patents rather than active-substance exclusivity.
Market implication
For US generics planning, the relevant question is typically not “will a new entrant be blocked,” but:
- Which ANDA routes map to the same listed reference product(s)
- Whether any listed patents remain in force for a given dosage form/strength at the time of submission
Which companies supply phytonadione, and how does the competitive landscape look?
The phytonadione market is typically characterized by:
- Multiple generic manufacturers supplying injectable and oral presentations
- Contract manufacturing and tender-driven procurement in hospital segments
- Brand presence mainly where health-system branding persists or where supply security and packaging preferences matter
Competitive dynamics
- Injectable phytonadione often has higher throughput in acute care settings, with tender-based switching
- Oral products are often cheaper and distributed broadly, with lower margin volatility outside price-sensitive markets
How much is the phytonadione market, and where is demand concentrated?
Demand drivers are anchored in the standard clinical need for vitamin K replacement and anticoagulant reversal protocols, including:
- Warfarin-associated bleeding risk management workflows
- Newborn prophylaxis use patterns
- Management of deficiency in malabsorption, liver disease, and nutrition-related deficiency states
Where demand is usually concentrated
- Hospitals and infusion centers for injectable phytonadione
- Maternity and neonatal units for prophylaxis
- Outpatient settings for deficiency correction and oral formulations
What market forecasts are realistic for phytonadione through 2030?
A high-confidence projection for phytonadione generally follows:
- Low-to-mid single digit growth in unit demand tied to population base, anticoagulant use patterns, and guideline adherence
- Margin pressure from generic competition
- Volatility from supply disruptions and tender outcomes
- Shifts by hospital formularies toward the lowest total-cost presentation that meets clinical protocol requirements
Most likely baseline trajectory
- Unit growth tracks steady clinical use
- Revenue growth tends to lag unit growth due to ongoing price compression
- Growth in some geographies can outpace maturity where generic penetration is still ramping and reimbursement dynamics differ
What generic entry risks exist for phytonadione products?
Generic entry risk is usually limited in a mature vitamin product category. Key risks are operational:
- Manufacturing quality and sterility/regulatory compliance (especially for injectables)
- Formulation matching and stability requirements
- Packaging and supply chain continuity for hospital contracts
For injectable products, the highest execution risk tends to come from:
- Sterility assurance
- Endotoxin control
- Shelf-life and transport stability in real-world conditions
Which clinical endpoints and trial designs matter most for phytonadione evidence?
Across studies, the clinical endpoints most often used include:
- INR reduction and time to INR normalization
- Prothrombin time improvement
- Bleeding event rates in deficiency populations
- Safety endpoints: hypersensitivity, injection-site reactions, and adverse event monitoring in neonates and elderly populations
How does phytonadione compare with alternative vitamin K and anticoagulant reversal agents?
The practical comparison set typically includes:
- Vitamin K1 (phytonadione) vs. vitamin K analogs (where used)
- PCC (prothrombin complex concentrate) and FFP strategies in warfarin-associated bleeding workflows (protocol-dependent)
- For DOAC bleeding: specific reversal agents depending on anticoagulant and geography (these are separate drug classes and not a direct replacement for vitamin K in many protocols)
Commercial implication
Even if phytonadione is the standard corrective agent for vitamin K deficiency, hospital protocols for major bleeding often use multi-agent strategies, which can affect phytonadione volume shares.
What regulatory pathways govern phytonadione in major markets?
Typical pathways:
- US: ANDA for generics referencing an approved product; supplemental changes for strengths/forms
- EU: generic/hybrid pathways under national or centralized procedures depending on member-state status
- Other markets: local generic registration frameworks with bioequivalence and quality data requirements
Execution note
Regulatory approvals for mature drugs are generally predictable once formulation and bioequivalence criteria are met, subject to facility inspection and product-specific stability documentation.
What patent litigation affects phytonadione, and is there risk of settlement-driven entry delays?
For phytonadione, large-scale patent litigation is not typically the defining driver of entry delays in the way it is for newer branded therapeutics. Where litigation appears, it is usually:
- Product-specific patent disputes
- Narrow formulation/process disagreements
- Listed-patent enforcement tied to a specific NDA/strength/route
How should you model revenue and volume for phytonadione launches or expansions?
A practical forecasting approach in this category:
- Start with historical unit consumption proxies by care setting (hospital injectable vs outpatient oral)
- Apply price erosion assumptions reflecting tender pressure
- Add small growth factors for guideline adherence and demographic base
- Include periodic shocks for supply disruptions and procurement re-tendering
Scenario framing that fits this market
- Base case: steady unit demand, continued price compression
- Bull case: supply stability plus formulary retention in large hospital systems
- Bear case: supply interruptions or aggressive price tender cycles
Key tables for business planning
Phytonadione demand drivers by setting
| Clinical setting |
Primary use |
Formulation tilt |
Demand factor |
| Hospital acute care |
Vitamin K replacement and coagulopathy protocols |
Injectable |
Warfarin management volume, bleeding protocol adherence |
| Neonatal units |
Prophylaxis of vitamin K deficiency |
Injectable/oral depending on local practice |
Birth rate, neonatal guideline compliance |
| Outpatient deficiency |
Correction of deficiency/malabsorption |
Oral |
Chronic risk states, provider prescribing patterns |
Forecast mechanics (template)
| Variable |
Typical direction in mature generic markets |
How to parameterize |
| Unit volume |
Low-to-mid growth |
Population base, anticoagulant use trends |
| ASP |
Downward |
Generic competition and tender outcomes |
| Market share |
Shifts via supply and contracts |
Bid wins, formulary conversion |
| Supply risk |
Intermittent |
Manufacturing capacity and inspection cycles |
Key Takeaways
- Phytonadione is a mature, generic-dominated vitamin K1 market where growth is driven by steady clinical need and procurement dynamics rather than new pharmacology.
- Competitive pressure is persistent; revenue growth typically lags unit growth due to price compression.
- The highest business execution risks are manufacturing and product-specific regulatory/compliance barriers for injectables, not active-substance patent blocking in most cases.
- Forecasting should model tender-driven ASP erosion, unit demand stability, and episodic supply shocks.
FAQs
1) Does phytonadione have ongoing clinical trials for new indications?
Trials are typically limited to formulation, administration route, and real-world coagulopathy management evidence rather than new primary indications for the active vitamin K1 molecule.
2) Are injectable and oral phytonadione treated as separate market categories?
Yes. Procurement patterns, tender cycles, and safety/regulatory manufacturing requirements differ materially between injectable and oral presentations.
3) What affects hospital uptake of phytonadione?
Hospital protocols for anticoagulant-associated coagulopathy, supply reliability, contracting, and total-cost considerations drive utilization more than incremental efficacy claims.
4) What is the most common endpoint used in phytonadione studies?
Time to correction of coagulation markers, typically INR or prothrombin time, plus safety monitoring.
5) How do DOAC reversal agents change phytonadione demand?
They can reduce bleeding management reliance on vitamin K pathways for DOAC-associated events, but they do not eliminate vitamin K1 use for vitamin K deficiency and warfarin-associated protocols where vitamin K remains relevant.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. Search results for phytonadione. U.S. National Library of Medicine.
